2-二乙基氨基二苯基戊酸酯盐酸 | 132-45-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-二乙基氨基二苯基戊酸酯盐酸
• 中文别名: 2-二乙基氨基乙基2-苯基戊酸酯盐酸盐
• 英文名称: Prospasmine
• 英文别名: 2-Phenyl-valeriansaeure-(2-diaethylamino-aethylester); Hydrochlorid；2-phenyl-valeric acid-(2-diethylamino-ethyl ester); hydrochloride；2-(diethylamino)ethyl 2-phenylpentanoate;hydron;chloride
• CAS: 132-45-6
• 化学式: C₁₇H₂₇NO₂*ClH
• 分子量: 313.868
• InChiKey: IATOMHNNMDOQEO-UHFFFAOYSA-N

物化性质

• 熔点：
  108-112 °C

计算性质

• 辛醇/水分配系数(LogP)：
  3.88
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922199090

文献信息

• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders
  申请人：Fraser Oliver Matthew

  公开号：US20050113421A1

  公开（公告）日：2005-05-26

  A method is provided for using Cav2.2 subunit calcium channel modulators, particularly thiazolidinone, oxazolidinone, and imidazolone derivatives, to treat non-inflammatory gastrointestinal tract disorders.

  提供了一种方法，用于使用Cav2.2亚单位钙通道调节剂，特别是噻唑啉酮、噁唑啉酮和咪唑啉酮衍生物，来治疗非炎症性胃肠道疾病。
• Compositions and methods to effect the release profile in the transdermal administration of active agents
  申请人：——

  公开号：US20020004065A1

  公开（公告）日：2002-01-10

  Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.

  本发明涉及一种用于经皮递送活性药剂的组合物和方法，该组合物和方法能够在持续时间为七天或更长时间内以几乎零阶释放速率递送活性药剂，包括一种药学上可接受的粘合基质和一种聚合物塑料材料，该聚合物塑料材料对活性药剂具有释放速率调节作用。
• Transdermal device containing polyvinylpyrrolidone as solubility enhancer
  申请人：NOVEN PHARMACEUTICALS, INC.

  公开号：EP1329225A2

  公开（公告）日：2003-07-23

  A blend of at least three polymers, including a soluble polyvinylpyrrolidone, in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. Soluble polyvinylpyrrolidone increases the solubility of drug without negatively affecting the adhesivity of the composition or the rate of drug delivery from the pressure-sensitive adhesive composition

  包括可溶性聚乙烯吡咯烷酮在内的至少三种聚合物与药物的混合物为透皮给药系统提供了一种压敏粘合剂组合物，当压敏粘合剂组合物与人体皮肤接触时，药物可从压敏粘合剂组合物中通过真皮输送。可溶性聚乙烯吡咯烷酮增加了药物的溶解度，而不会对组合物的粘附性或压敏胶组合物的给药速率产生负面影响。
• Medical implant
  申请人：Boston Scientific Limited

  公开号：EP1803415A1

  公开（公告）日：2007-07-04

  A medical assembly includes an implant and an envelope at least partially enclosing a portion of the implant. The envelope may include a tongue to protect the implant, a scaffold to provide integrity to the envelope, a tab access to ease envelope withdrawal, and/or one or more discontinuities to ease envelope withdrawal.

  一种医疗组件包括植入体和至少部分封闭植入体部分的包膜。包膜可包括保护植入体的舌片、为包膜提供完整性的支架、便于抽出包膜的卡口和/或便于抽出包膜的一个或多个不连续面。